Le Minh-Anh, Al-Moussally Feras, Carilli Allison
Internal Medicine, University of Central Florida (UCF)HCA Florida Healthcare (Greater Orlando) Internal Medicine Residency Program, Orlando, USA.
Oncology, University of Central Florida College of Medicine, Orlando, USA.
Cureus. 2024 Jul 26;16(7):e65416. doi: 10.7759/cureus.65416. eCollection 2024 Jul.
Peripheral T-cell lymphomas (PTCLs) are an aggressive form of non-Hodgkin lymphomas. PTCLs have multiple subtypes, with PTCL not otherwise specified (PTCL-NOS) being the most common. This subtype usually has a high rate of relapse. Making an accurate diagnosis requires molecular genetic analyses, histopathological examination, and immunophenotyping. Treatment for PTCL traditionally starts with the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone). We present a case of a patient with PTCL-NOS who progressed despite multiple treatment regimens, including both traditional and novel therapeutic agents, and finally achieved good results with azacytidine, selected based on a mutation. This case proposes future research into Azacytidine's efficacy in this patient population and further exploration of the broader utility of epigenetic therapies in PTCL.
外周T细胞淋巴瘤（PTCL）是一种侵袭性非霍奇金淋巴瘤。PTCL有多种亚型，其中未另行指定的外周T细胞淋巴瘤（PTCL-NOS）最为常见。这种亚型通常复发率很高。准确诊断需要进行分子遗传学分析、组织病理学检查和免疫表型分析。PTCL的传统治疗始于CHOP方案（环磷酰胺、阿霉素、长春新碱和泼尼松）。我们报告一例PTCL-NOS患者，尽管接受了包括传统和新型治疗药物在内的多种治疗方案，但病情仍进展，最终使用基于一种突变选择的阿扎胞苷取得了良好效果。该病例为未来研究阿扎胞苷在该患者群体中的疗效以及进一步探索表观遗传疗法在PTCL中的更广泛应用提出了建议。
